AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

167.3 USD

Average target price

184.1 USD

Spread / Average Target

+10.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+7.95%	296B
NOVO NORDISK A/S	+25.45%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ASTRAZENECA PLC	+13.02%	233B
NOVARTIS AG	+5.34%	201B
ROCHE HOLDING AG	-9.94%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B
SANOFI	+0.79%	123B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			Pre-market 07:58:19 am
167.3 ^USD	-0.30%		169	+1.02%

01:54pm	Earnings Flash (ABBV) ABBVIE Reports Q1 Revenue $12.31B, vs. Street Est of $11.94B	MT
01:53pm	Earnings Flash (ABBV) ABBVIE Reports Q1 EPS $2.31, vs. Street Est of $2.26	MT

Earnings Flash (ABBV) ABBVIE Reports Q1 Revenue $12.31B, vs. Street Est of $11.94B	07:54am	MT
Earnings Flash (ABBV) ABBVIE Reports Q1 EPS $2.31, vs. Street Est of $2.26	07:53am	MT
AbbVie raises annual profit forecast on strong Skyrizi sales	07:36am	RE
Tech Strength Boosts Wall Street Pre-Bell; Asia, Europe Up	07:23am	MT
Stocks Rebound Pre-Bell Ahead of Pending Inflation Report; Asia, Europe Gain	07:20am	MT
North American Morning Briefing : Tech Still in -2-	06:26am	DJ
Futures climb as Alphabet, Microsoft results lift megacaps	06:00am	RE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25	RE
AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint	Apr. 25	MT
AbbVie Inc. Announces Positive Topline Results from Level Up	Apr. 25	CI
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
US CDC warns of harmful reactions to fake Botox injections	Apr. 23	RE
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study	Apr. 18	MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint	Apr. 18	DJ
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis	Apr. 18	CI
OSE: licensing agreement with AbbVie enters into force	Apr. 17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	Apr. 17	MT